Join Nuvectis Pharma for a virtual key opinion leader (KOL) event featuring Alexander Spira, MD, PhD, FACP, FASCO (Chief Scientific Officer, NEXT Oncology) and Professor Asier Uncita-Broceta, MPharm, MSc, PhD (Professor of Chemistry, University of Edinburgh), who will join Company management to discuss the NXP900 development program. The discussion will focus on key NXP900 preclinical and clinical data to date and the strategy for the monotherapy and combination components of the NXP900 Phase 1b clinical program.

NXP900 is a selective, orally administered type 1.5 SRC/YES1 kinase inhibitor. NXP900’s unique mechanism of action was designed to completely shut down the YES1/SRC pathway by inhibiting both the catalytic and scaffolding functions of the SRC pathway, while avoiding paradoxical activation of pro-oncogenic signaling, a phenomenon observed with type 1 inhibitors.

A live question and answer session will follow the formal presentations.